Prostate cancer is an inevitably lethal disease that afflicts men in the western world greater than any other malignancy. The inability of therapies to eliminate prostate cancer and the recurrence of disease many years post-radical prostatectomy are indicative of the existence of cancer stem/initiating cells. In the healthy prostate, a subset of slowgrowing androgen receptor (AR) negative basal cells possess an unlimited ability to self-renew and differentiate into neuroendocrine cells and transit-amplifying cells that ultimately yield the ARexpressing secretory cells that populate the majority of the glandular epithelium. 1 One model suggests that cancer stem/initiating cells arise from these normal stem cells within the basal layer of the prostate epithelium after they have accrued mutations that promote carcinogenesis. 2 Complicating the study of stem cells is their low abundance in the heterogeneous prostate epithelium. The pentaspan transmembrane protein CD133 has been used extensively as a marker to identify and isolate prostate stem cells and cancer/stem initiating cells. [3] [4] [5] Possessing an extracellular N-terminal domain (EC1), two large heavily glycosylated extracellular loops (EC2 and EC3), and often existing as different splice variants, the biological function of CD133 is unknown. 6, 7 Identified originally as an antigen present on the surface of CD34 pos hematopoietic stem cells, the expression of CD133 has been documented in adult stems cells and cancer stem/initiating cells from a number of diverse tissue and cancer types. 4, 8 Underscoring its association with stem cells in the prostate, basal cells isolated from benign prostate tissue that expressed α2β1 integrin and CD133 were able to regenerate a fully differentiated prostate epithelium in vivo. 8 Additionally, purported prostate cancer stem cells expressing a CD133 pos /α 2 β 1 high /CD44 phenotype were isolated from human tumor biopsies and demonstrated tumorigenic properties. 9 Investigating the functional role CD133 plays in the development of the adult prostate and in the initiation and progression of cancer is hindered by several factors. Very few cell lines uniformly express endogenous CD133. Prostate cancer cell lines and non-immortalized prostate epithelial cells do possess a minor population of CD133-expressing cells (∼1-5%). 10 When the CD133 pos cells are isolated and expanded in culture, CD133 expression is lost returning to the original minor population. 5 Reliable antibodies for the detection and isolation of CD133 also do not exist-this has been the main crux in investigating the biology of CD133. 11, 12 The two most commonly used antibodies for the isolation and analysis of CD133, AC133
(epitope CD133/1) and AC141 (epitope CD133/2), both recognize glycosylated epitopes. 5 During the lifetime of a protein, glycosylation motifs can be pared or lost altogether making them inconsistent epitopes for analysis. 11, 13 Several investigators have documented that the AC133 epitope disappears upon cancer stem cell differentiation even though CD133 protein and mRNA are still present. [14] [15] [16] Further illustrating the paucity of high quality antibodies for CD133, studies have found discordant CD133 expression by IHC using different CD133 antibodies tested in sections of the same tissues. 11, 12, 17 The dynamic nature of the glycosylation motifs on the extracellular domains of CD133 coupled with the lack of a sensitive antibody suggest that CD133-expressing cell populations may be more abundant than previously imagined in tissues, but those cell populations are going undetected given the current antibody technology.
In this study, we detail the characterization of a novel antibody for CD133 that was identified from a human antibody phage display library. Our antibody, termed HA10, was found to bind to a glycosylation-independent epitope on the protein backbone of CD133. Using our antibody we were able to detect CD133 expression in cell lines by flow cytometry and in formalin fixed paraffin embedded tissue sections. In several instances, HA10 was able to detect CD133 expression that was not identified by the commercially available AC133 antibody. In concordance with previous studies, little CD133 expression in healthy prostate and prostate adenocarcinoma sections was observed. We did, however, make a novel finding documenting extensive CD133 expression in AR neg LuCaP patient-derived xenograft (PDX) models and in a liver biopsy from a patient with AR neg that also expressed the neuroendocrine marker chromogranin A.
| MATERIALS AND METHODS

| Cell culture
All cancer cells lines used in this study were purchased from American Type Culture Collection (ATCC) except for the CWR-R1 CD133 cells which were a generous gift from Dr. Donald Vander Griend, University of Chicago. Cells were maintained in their respective recommended media, supplemented with 10% FBS (Gibco), 1% antibiotic-antimycotic (Gibco), and 1% glutaMAX (Gibco) at 37°C and 5% CO 2 . Additionally, enzalutamide resistant (EnzR) cell lines were supplemented with 10 μM enzalutamide (APExBIO) at all times. The cell lines were authenticated using short-tandem repeat profiling provided by the vendor and routinely monitored for mycoplasma contamination.
The PC3 CD133 knock-in cell line was generated using PROM1 Lentifect Purified Lentiviral Particles (LPP-M0038-Lv105-200-S, GeneCopoeia).
PC3 cells were seeded at 5 × 10 4 cells/well in a 24-well plate using heat-inactivated FBS. Once cells became 70-80% confluent, transduction was performed according to the manufacturers protocol using 7 μg/mL Polybrene (H9268-5G, Sigma-Aldrich) and 10 μL of lentivirus for 24 h. Following overnight incubation, transduced cells were reseeded into three wells of a six-well plate and incubated for 48 h.
Transduced clones were stably selected with 3 μg/mL puromycin for the duration of culture.
| Phage display biopanning
A fully human naïve single chain variable fragment (scFv) phage display library was used to identify clones against native human CD133.
Recombinant human CD133 (Product, R&D Systems) was biotinylated using EZ-link™ NHS-PEG 4 
| IgG production
The heavy chain and light chain variable domains of the HA10 sequence were cloned separately into pFUSE2ss derived rabbit IgG expression vectors (invivogen) and co-transfected into HEK293T (Life Technologies) cells for 72 h. Following incubation, the serum was collected, filtered through a 0.45 µm filter, and purified using a 1 mL HiTrap Protein A HP column (GE Healthcare). The column was equilibrated with 20 mM sodium phosphate, pH 7.4. The serum was loaded onto the column and washed with equilibration buffer for 10 column volumes and bound protein was eluted with 0.1 M citric acid, pH 3. Eluted IgGs were collected, concentrated using a 50 kDa centrifugal filter, and buffer exchanged into D-PBS, and analyzed as described above.
| Surface plasmon resonance
SPR measurements were obtained using a BIAcore T100 instrument.
The native recombinant CD133 protein was captured on a CM5 sensor chip by amine coupling at pH 4.5 to a final immobilization density of 
| Immunoprecipitation
Cell lysates were prepared using non-denaturing 1% triton X-100 lysis buffer with protease and phosphatase inhibitors. The concentrations of cell lysates were determined using an RCDC assay. Purified HA10 (2 μg) was incubated with 0.5 mg of cell lysate overnight at 4°C to facilitate antibody conjugation. Protein A/G Plus-Agarose beads (#sc-2003, Santa Cruz Biotechnology) were added to the lysate-antibody mixture and incubated for 3 h at 4°C.
The immunoprecipitant was washed three times with D-PBS and captured proteins were eluted using 40 μL of 1× laemmli buffer.
The sample was boiled at 95°C for 5 min and centrifuged at 100g
for 5 min to remove majority of the agarose beads from the precipitant. The eluate was analyzed by SDS-PAGE followed by subsequent western blotting using a commercialized anti-CD133
antibody as well as mass spectrometry using a Linear Ion Trap mass spectrometer (Thermo Scientific) and PEAKS proteomics software package.
| Immunohistochemistry
The 
| Statistical analysis
Welch's unpaired t-tests using GraphPad Prism 7 were used to calculate statistics for CD133 mRNA expression from qRT-PCR experiments. Each cell line was compared to the calibrator (PC3) to determine statistically significant levels of CD133 mRNA expression.
All other assays were carried out 2-3 times and data replication was observed in repeated experiments.
3 | RESULTS
| Antibody identification and in vitro characterization
A human single-chain variable fragment (scFv) antibody phage display library with a diversity of 8 × 10 9 was initially screened for three rounds against glycosylated recombinant CD133. Biopanning was performed using biotinylated CD133 attached to magnetic streptavidin coated beads to ensure that the protein retained some three-dimensional
structure. An additional round of biopanning was performed with CD133 that had been deglycosylated by PNGase F treatment to enrich for clones against a glycosylation-independent epitope. After the fourth round, 288 independent clones were screened by ELISA using gene expression analysis found that the mRNA level of E006AA-hT were similar to that of PPT2 and CaCo-2 ( Figure 2B ). These results suggest that HA10 may be more effective at detecting CD133 in naturally expressing CD133 pos cell populations, potentially due to the effects of CD133 glycosylation, epitope masking, or protein truncation.
| Antibody staining in fixed tissues
The variable heavy and light chains of HA10 scFv were cloned into rabbit IgG scaffold vectors for expression in a mammalian system. Figure S1 ). Staining was largely absent in healthy human tissues, except for weak and variable staining in colon. The After a year on this regimen, his PSA had decreased from 87 to 17 ng/mL, however, a CT scan found extensive liver metastasis ( Figure 6A ). Biopsies of the liver lesions were found to be positive for CD133 based on staining with HA10 ( Figure 6B , Suppl. Figure S3) . Recent studies have suggested that less than a quarter of all commercially available antibodies actually bind to their target antigen or work for their intended application. 23, 24 Hybridoma-derived antibodies often cannot distinguish between highly homologous members of the same protein family or proteins with significant posttranslational modifications such as glycosylation. 25 Antibody phage display is a powerful technique that can rapidly identify recombinant hybridoma technology has failed. Since it is an in vitro technology, the selection process in antibody phage display can be modified to enrich for highly unique clones that bind to specific epitopes. Here, we used antibody phage display to select for an antibody fragment that bound to a glycosylation-independent epitope on the protein backbone of CD133. The unique antibody discovered through this selection process, HA10, was able to detect CD133 in cell lines and fixed tissues.
Since its discovery in the late 1990s, CD133 has been viewed as a marker for stem cells of the healthy prostate as well as cancer. 5, 8 The isolation and analysis of CD133 expressing cells has primarily been conducted using the AC133 antibody. It is has been established that the AC133 epitope, but not CD133 protein, is lost when stem cells differentiate. 14 Splice variants of CD133 are also known to exist that could potentially affect the epitopes used for detection. 26 Based on this evidence, it is plausible that the AC133 epitope represents a population of CD133 that is only found in undifferentiated stem cells.
As the basal stem cells in the prostate differentiate into transitamplifying cells and ultimately luminal cells, the AC133 epitope is lost, but CD133 variants with de novo epitopes are present in the progeny.
These new CD133 populations cannot be detected by AC133 or Previous IHC studies using the AC133 antibody discovered that CD133 was a marker for a truly rare basal cell type with less than 1% of all basal cells staining positive for CD133. 8 No report has ever androgen. 30 The absence of CD133 in the original TURP specimen of the patient suggests that the CD133 in the liver biopsies may originate from divergent clonal evolution, but it is difficult to say since biopsies at multiple stages of the disease were not taken. 31 In order to come to any conclusion about the expression of CD133
in AR neg cancer with neuroendocrine differentiation, more samples from a number of metastatic sites need to be analyzed.
